Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

20121,421 citationsJournal Articlegreen Open Access

Authors

Aleksandar Sekulić · Mayo Clinic in Arizona

Michael R. Migden · The University of Texas MD Anderson Cancer Center

Anthony E. Oro · Stanford University

Luc Dirix · GZA Ziekenhuizen Campus Sint-Augustinus

Karl D. Lewis · University of Colorado Denver

John D. Hainsworth · Sarah Cannon Research Institute

James Solomon

Abstract

Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma. (Funded by Genentech; Erivance BCC ClinicalTrials.gov number, NCT00833417.).

Topics & Keywords

Hedgehog Signaling Pathway Studies Cancer and Skin Lesions Nonmelanoma Skin Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 23, pp. 2171-2179

DOI: 10.1056/nejmoa1113713

Field-Weighted Citation Impact: 51.52